Get the Stockscreener App
13.72
1.79%
-0.25
After Hours:
13.74
0.02
+0.15%
Silence Therapeutics Plc Adr stock is traded at $13.72, with a volume of 823.94K.
It is down -1.79% in the last 24 hours and up +40.72% over the past month.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
See More
Previous Close:
$13.97
Open:
$14.01
24h Volume:
823.94K
Relative Volume:
0.98
Market Cap:
$648.06M
Revenue:
$840.00K
Net Income/Loss:
$-75.20M
P/E Ratio:
-8.6175
EPS:
-1.5921
Net Cash Flow:
$-65.69M
1W Performance:
+14.81%
1M Performance:
+40.72%
6M Performance:
+208.31%
1Y Performance:
+143.69%
1-Day Range:
$13.44
$14.22
1-Week Range:
$13.36
$17.58
52-Week Range:
$4.19
$17.58
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Name
Silence Therapeutics Plc Adr
Sector
Industry
Phone
44-0-20-3457 6900
Address
12 HAMMERSMITH GROVE, LONDON
Compare SLN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
13.72 | 641.45M | 840.00K | -75.20M | -65.69M | -1.5921 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Goldman | Sell |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Stock (SLN) Latest News
Silence Therapeutics closes $201.3M public offering By Investing.com - Investing.com India
Silence Therapeutics closes $201.3M public offering - Investing.com
Silence Therapeutics Director Richard Ian Griffiths Reports Multiple ADS Sales on August 10, 2026 - Kalkine Media
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Yahoo Finance
Silence Therapeutics Announces Pricing of $13.50 Per ADS in Public Offering - Kalkine Media
Form 8K Silence Therapeutics plc For: 12 August By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9%What's Next? - marketbeat.com
Silence Therapeutics prices $175M public offering at $13.50 per ADS - Investing.com
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeWhat's Next? - marketbeat.com
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - sharewise.com
Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing - TechStock²
Silence Therapeutics launches $150 million public offering - Investing.com
Silence Therapeutics launches $150 million public offering By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Gap UpStill a Buy? - marketbeat.com
Silence Therapeutics Reports Q2 2026 Financial Results in SEC Filing - Kalkine Media
Silence Therapeutics Announces Positive Phase 2 SANRECO Trial Outcomes for Divesiran in Polycythemia Vera - Kalkine Media
Silence Therapeutics SLN Stock Heats Up Ahead Phase 2 Data - StocksToTrade
Silence Therapeutics (SLN) Rallies Ahead Of Key Phase 2 Data - timothysykes.com
Silence Therapeutics reports positive phase 2 trial results - Investing.com
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Finviz
Why is Silence Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Silence Therapeutics (NASDAQ:SLN) Reaches New 1-Year HighStill a Buy? - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ADAR1 Capital Management LLC Buys 148,514 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - marketbeat.com
Silence Therapeutics (NASDAQ:SLN) Sees Large Volume IncreaseStill a Buy? - marketbeat.com
Silence Therapeutics (NASDAQ:SLN) Reaches New 12-Month HighTime to Buy? - marketbeat.com
Silence Therapeutics (NASDAQ:SLN) Stock Price Up 6.9%Here's Why - marketbeat.com
SLN stock skyrockets 107% in six months: Here's what you need to know - MSN
Silence Therapeutics (SLN) moves 7.2% higher: Will this strength last? - MSN
ETFs Investing in Silence Therapeutics PLC Sponsored ADR Stocks - TradingView
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know - Yahoo Finance UK
Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance Singapore
Silence Therapeutics (NASDAQ:SLN) Shares Up 10%Here's What Happened - MarketBeat
Form 13D/A Silence Therapeutics Plc For: 8 July By Investing.com - Investing.com South Africa
Silence Therapeutics (SLN) surges 26.0%: Is this an indication of further gains? - MSN
Silence Therapeutics PLC Sponsored ADR Actuals & Estimates (NASDAQ:SLN) - TradingView
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains? - Yahoo Finance Singapore
Why is Silence Therapeutics stock surging today? - Investing.com
Silence Therapeutics stock jumps on Cantor Fitzgerald upgrade - Investing.com
Form 8K Silence Therapeutics plc For: 23 June By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Silence Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Silence Therapeutics stock rating at buy - Investing.com
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Sahm
Silence Therapeutics presents divesiran trial data at EHA By Investing.com - Investing.com South Africa
Silence Therapeutics presents divesiran trial data at EHA - Investing.com
Silence Therapeutics (SLN) soars 19.0%: Is further upside left in the stock? - MSN
SLNSilence Therapeutics Plc ADR Stock Price and Quote - Finviz
Silence Therapeutics (NASDAQ: SLN) registers $300M shelf, $100M ADSs included - Stock Titan
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference - ChartMill
Revenue per share of Silence Therapeutics PLC Sponsored ADR – DUS:XRP2 - TradingView
Silence Therapeutics Plc Adr Stock (SLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):